Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines

Cancer Investigation

Volumn 15, Issue 5, 1997, Pages 491-499

  Ravindranath, Mepur H ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GANGLIOSIDE GM3; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MELANOMA VACCINE;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOLOGY; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; MELANOMA; MELANOMA CELL; MEMBRANE BINDING; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

EID: 0030826791     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709047588     Document Type: Article

References (72)

1. Morton DL, Ravindranath MH: Active specific immunotherapy with vaccines. In: Cancer Medicine, 4th ed, edited by JF Holland, E Frei, R Bast, D Kufe, DL Morton, R Weichselbaum, Baltimore, Williams & Wilkins, 1997, pp. 1179-1198.
2. Hakomori S-I: Glycolipids of tumor cell membrane. Adv Cancer Res 18:265-315, 1973.
3. Morton DL, Malmgren RA, Holmes EC, et al: Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64:233-240, 1968.
4. Morton DL, Eilber FR, Malmgren RA, et al: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158-164, 1970.
5. Morton DL, Eilber FR, Holmes EC, et al: BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 180:635-643, 1974.
6. Morton DL, Eilber FR, Holmes EC, et al: Preliminary results of a randomized trial of adjuvant immunotherapy in malignant melanoma. Semin Surg Oncol 5:420-435, 1978.
7. Morton DL, Nizze JA, Gupta RK, et al: Active specific immunotherapy of malignant melanoma: In: Current Status of Cancer Control and Immunobiology, Seoul, 1987, pp 152-161.
8. Irie RF, Irie K, Morton DL: A membrane antigen common to human cancer and fetal brain tissue. Cancer Res 36:3510-3517, 1976.
9. Sidell N, Irie RF, Morton DL: Immune cytolysis of human malignant melanoma by antibody to oncofetal antigen I (OFA-I). I. Complement-dependent cytotoxicity. Cancer Immunol Immunother 7:151-155, 1979.
10. Sidell N, Irie RF, Morton DL: Oncofetal antigen I: A target for immune cytolysis of human cancer. Br J Cancer 40:950-953, 1979.
11. Sidell N, Irie RF, Morton DL: Immune cytolysis of human malignant melanoma by antibody to oncofetal antigen-I (OFA-I). II. Antibody dependent cell mediated cytotoxicity. Cancer Immunol Immunother 9:49-54, 1980.
12. Irie RF, Jones PC, Morton DL, et al: In vitro production of human antibody to a tumor-associated fetal antigen. Br J Cancer 44:262-266, 1981.
13. Irie RF, Sze LL, Saxton RE: Human antibody to OFA-1, a tumor antigen, produced in vitro by EBV-transformed human B-lymphoblastoid cell lines. Proc Natl Acad Sci USA 79:5666-5670, 1982.
14. Irie RF, Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83:8694-8698, 1986.
15. Irie RF, Matsuki T, Morton DL: Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786-787, 1989.
16. Portoukalian J, Zwingelstein G, Abdul-Malek N, et al: Alterations of gangliosides in plasma and red cells of human bearing melanoma tumors. Biochem Biophys Res Commun 85:916-920, 1978.
17. Portoukalian J, Zwingelstein G, Dore JF: Lipid composition of human malignant tumors at various levels of malignant proliferation. Eur J Biochem 94:19-24, 1979.
18. Carubia JM, Yu RK, Macala LJ, et al: Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 120:500-504, 1984.
19. Tsuchida T, Otsuka H, Niimura M, et al: Biochemical study on gangliosides in neurofibromas and neurofibrosarcomas of Rechlinghausen's disease. J Dermatol 11:129-136, 1984.
20. Tsuchida T, Ravindranath MH, Saxton RE, et al: Gangliosides of human melanoma: Altered expression in vivo and in vitro. Cancer Res 47:1278-1281, 1987.
21. Tsuchida T, Saxton RE, Irie RF, et al: Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 78:55-60, 1987.
22. Tsuchida T, Saxton RE, Morton DL, et al: Gangliosides of human melanoma. J Natl Cancer Inst 78:45-54, 1987.
23. Tsuchida T, Saxton RE, Morton DL, et al: Gangliosides of human melanoma II. Cancer 63:1166-1174, 1989.
24. Ravindranath MH, Paulson JC, Irie RF: Human melanoma antigen O-acetylated ganglioside GD3 is recognized by Cancer antennarius lectin. J Biol Chem 263:2079-2086, 1988.
25. Reivinen J, Holthofer H, Miettinen A: O-Acetyl GD3 ganglioside in human peripheral blood T lymphocytes. Int Immunol 6:1409-1416, 1994.
26. Bauman N, Harpin ML, Turpin JC: Ganglioside content and pattern in tumor tissue of human neuroblastomas. Biomedicine 35:215-217, 1981.
27. Berra B, Riboni L, De Gasperi R, et al: Modifications of ganglioside patterns in human meningiomas. J Neurochem 40:777-782, 1983.
28. Berra B, Gaini SM, Riboni L: Correlation between ganglioside distribution and histological grading of human astrocytomas. Int J Cancer 36:363-366, 1985.
29. Bouchon B, Portoukalian J, Bornet H: Major gangliosides in normal and pathological human thyroids. Biochem Int 10:531-538, 1985.
30. Davidsson P, Fredman P, Collins VP, et al: Ganglioside composition in human meningioma. J Neurochem 53:705-709, 1989.
31. Fredman P, von Holst B, Collins VP, et al: Potential ganglioside antigen associated with human gliomas. Neurol Res 8:123-126, 1986.
32. Goff BA, Lee WMF, Westrick MA, et al: Gangliosides of human chronic lymphocytic leukemia and hairy cells. Eur J Biochem 130:553-557, 1983.
33. Higashi H, Hirabayashi Y, Hirota M, et al: Detection of ganglioside GM2 in sera and tumor tissues of hepatoma patients. Jpn J Cancer Res 78:1309-1313, 1984.
34. Higashi H, Hirabayashi H, Sasabe T, et al: Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res 79:952-956, 1988.
35. Kanda S, Cochran AJ, Lee W, et al: Variations in the ganglioside profile of uveal melanoma correlate with cytologic heterogeneity and malignant potential. Int J Cancer 52:682-687, 1992.
36. Ladisch S, Wu ZL: Detection of a tumor-associated ganglioside in plasma of patients with neuroblastoma. Lancet 1:136-138, 1985.
37. Liepkalns VA, Icard C, Yates AJ, et al: Effects of cell density on lipids of human glioma and fetal neural cells. J Neurochem 36:1959-1965, 1981.
38. Miyake M, Hashimoto K, Ito M, et al: The abnormal occurrence and the differentiation-dependent distribution of N-acetyl and N-glycolyl species of the ganglioside GM2 in human germ cell tumors. Cancer 65:499-505, 1989.
39. Schengrund C, Repman MA, Shochat SJ: Ganglioside composition of human neuroblastomas. Correlation with prognosis. Cancer 56:2640-2646, 1985.
40. Shochat SJ, Abt AB, Schengrund CL: VCN-releasable sialic acid and gangliosides in human neuroblastomas. J Pediatr Surg 12:413-418, 1977.
41. Siddiqui B, Buehler J, DeGregorio MW, et al: Differential expression of ganglioside GD3 by human leukocytes and leukemia cells. Cancer Res 44:5262-5267, 1984.
42. Sunder-Plassman M, Bernheimer H: Ganglioside in meningiomen and heinhauten. Acta Neuropathol (Berl)27:289-294, 1974.
43. Traylor DL, Hogan EL: Gangliosides of human cerebral astrocytomas. J Neurochem 34:126-131, 1980.
44. Westrick MA, Lee WMF, Goff B, et al: Gangliosides of human leukemia cells. Biochim Biophys Acta 750:141-146, 1983.
45. Ravindranath MH, Tsuchida T, Morton DL, et al: Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 67:3029-3035, 1991.
46. Gullino PM: Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol 34:439-441, 1995.
47. Ravindranath MH, Morton DL, Irie RF: An epitope common to gangliosides O-acetyl GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49:3891-3897, 1989.
48. Cheresh DA, Harper JR, Schulz G, et al: Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81:5767-5771, 1984.
49. Morton DL, Foshag LG, Hoon DSB, et al: Prolongation of survival in metastatic melanoma following active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:462-482, 1992.
50. Ravindranath MH, Ravindranath RMH, Morton DL, et al: Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. J Immunol Methods 169:257-272, 1994.
51. Ravindranath MH, Guenther M, Kunnath S, et al: Anti-ganglioside IgM responses to a new melanoma cell vaccine (MCV) in melanoma patients. Proc Am Assoc Cancer Res 1993; 34:488, 1993.
52. Morton DL, Ravindranath MH, Irie RF: Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. Prog Brain Res 101:251-275, 1994.
53. Tai T, Cahan LD, Tsuchida T, et al: Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612, 1985.
54. Livingston PO, Calves MJ, Natoli EF: Approaches to augmenting immunogenicity of the ganglioside GM2 in mice: Purified GM2 is superior to whole cells. J Immunol 138:1524-1529, 1987.
55. Livingston PO, Natoli EJ, Calves MJ, et al: Vaccines containing purified GM2 gangliosides elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911-2915, 1987.
56. Livingston PO: Approaches Io augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147-166, 1995.
57. Schirrmacher V, Hoegan PV: Importance of tumor cell membrane integrity and viability for cytotoxic T lymphocyte activation by cancer vaccines. Vaccine Res 2:183-196, 1994.
58. Ravindranath MH, Morton DL, Irie RF: Attachment of monophosophoryl lipid A (MPL) to cells and liposomes augments antibody response to membrane-bound gangliosides. J Autoimmun 7:803-816, 1994.
59. Bogoch S: Demonstration of serum precipitin to brain gangliosides. Nature 183:392-393, 1950.
60. Shy ME, Evans VA, Lubin FD: Antibodies to GM1 and GD1b in patients with motor neuron disease with plasma cell dyscrasia. Ann Neurol 25:511-518, 1989.
61. Naiki M, Marcus D, Leeden R: Properties of antisera to ganglioside GM1 and asialo-GM1. J Immunol 113:84-93, 1974.
62. Yokoyama M, Trams EG, Brady RO: Immunochemical studies with gangliosides. J Immunol 113:84-93, 1963.
63. Sherwin AI, Lowden JA, Wolfe LS: The production of antisera to gangliosides from human nervous tissue. J Biochem 42:1640-1648, 1964.
64. Pascal TA, Saifer A, Gitlin J: Immunochemical studies on normal and Tay-Sachs brain gangliosides. Proc Soc Exp Biol Med 121:739-743, 1966.
65. Koscielak J, Hakomori S-I, Jeanloz RW: Glycolipid antigen and its antibody. Immunochemistry 5:441-455, 1968.
66. Helling F, Shang Y, Calves M, et al: Increased immunogenicity of GD3 conjugate vaccines: Comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res 54:197-203, 1993.
67. Portoukalian J, Carrel S, Dore JF, et al: Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. Int J Cancer 49:893-899, 1991.
68. Takahashi K, Ono K, Hirabayashi Y, et al: Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J Immunol 140:3244-3249, 1988.
69. Ravindranath MH, Brazeau SM, Morton DL: Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside. Experientia 50:648-653, 1994.
70. 2+. Glycoconjugate J 11:97-104, 1994.
71. 2) better than soluble lysate cancer vaccine. AntiCancer Drugs 8:217-224.
72. a are differentiation antigens immunogenic in human melanoma. Cancer 79:1686-1697.